Project Details
| Status | Active |
|---|---|
| Effective start/end date | 4/12/18 → 4/12/24 |
Funding
- National Marrow Donor Program (Prot #BMT CTN 1506/2215-CL-0304)
- Astellas Pharma Global Development, Inc. (Prot #BMT CTN 1506/2215-CL-0304)
Prot #BMT CTN 1506/2215-CL-0304: A Multi-Center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
- Frankfurt, Olga (PD/PI)
Project: Research project